ProCE Banner Activity

REGENERATE: Obeticholic Acid Improves Liver Fibrosis in Expanded Analysis of Patients With NASH

Slideset Download
Conference Coverage
Obeticholic acid 10 mg and 25 mg improved liver fibrosis, steatohepatitis, and liver biochemistry in expanded ITT population that included patients with fibrosis stages 1-3.

Released: November 12, 2019

Expiration: November 10, 2020

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Gilead Sciences, Inc.

Intercept Pharmaceuticals